Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsEmpire Bluecross Avlayah Coverage | OpenPayer
    Ask Trek AI about this page
    CurrentEmpire BluecrossPolicy CC-0302

    Avlayah (tividenofusp alfa-eknm) Coverage for Neurologic Manifestations of MPS II

    Customize your policy alerts

    Sign up for Empire Bluecross Policy CC-0302 alerts

    Get alerted when Policy CC-0302 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Medical-necessity and prior-authorization review for Avlayah under the member’s medical benefit, including initial and continuation therapy, quantity limits, coverage exclusions, and coding.

    Policy Summary
    PayerEmpire Bluecross
    PolicyAvlayah (tividenofusp alfa-eknm) Coverage for Neurologic Manifestations of MPS II
    Policy CodePolicy CC-0302
    Change TypeCoding update
    Effective DateOct 27, 2026
    Last ReviewSep 14, 2026
    Next Review DateN/A
    Key ActionSubmit Avlayah requests for clinical review and prior authorization with documentation supporting the applicable initial or continuation criteria.
    SourceLink
    POLICY UPDATE CHANGES

    The policy removed HCPCS codes C9399 and J3590 from the Avlayah coding set.

    The policy added HCPCS code J1757 for injection of tividenofusp alfa-eknm.

    Under 18Initial-therapy age requirement
    ≥5 kgMinimum initial-treatment weight
    15 mg/kg weeklyDose and quantity limit
    E76.1MPS II diagnosis code

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    2Diagnostic pathways

    Coverage Criteria

    Initial Therapy

    Initial requests may be approved when all of the following criteria are met.

    Initial therapy

    • Age and weight: Individual is less than 18 years of age and weighs at least 5 kg.Age <18 years and weight >=5 kg
    • Confirmed MPS II diagnosis

      • Enzyme activity pathway: Deficiency in iduronate 2-sulfatase enzyme activity measured in fibroblasts or leukocytes combined with normal enzyme activity of another sulfatase, with documentation provided.
      • Genetic pathway: Pathologic iduronate 2-sulfatase gene mutation, with documentation provided.
    • Neurologic indication and impairment status: Individual is requesting Avlayah for neurologic manifestations of MPS II and does not have advanced neurologic impairment.

    Continuation Therapy

    Continuation requests may be approved when the following criterion is met.

    Continuation therapy: Documentation is provided that there is clinically significant improvement or stabilization in clinical signs and symptoms of disease compared to the predicted natural history trajectory of disease.

    Examples include reduction in cerebrospinal fluid heparan sulfate or improvement in neurologic function.

    Avlayah (tividenofusp alfa-eknm) is not approved for use in combination with Elaprase.

    Avlayah is not approved when the stated coverage criteria are not met or for any other indication.

    Coding Information

    HCPCS CodesHCPCS
    J1757Injection, tividenofusp alfa-eknm, 1 mg [Avlayah]
    S9357Home infusion therapy, enzyme replacement intravenous therapy, (e.g., Imiglucerase); administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem
    ICD-10 Diagnosis CodesICD-10
    E76.1Mucopolysaccharidosis, type II [Hunter's syndrome]
    Avlayah Dose and Quantity Limit
    DrugAvlayah (tividenofusp alfa-eknm)
    Vial strength150 mg vial
    Dose limit15 mg/kg
    FrequencyOnce weekly

    Provider Actions and Review Requirements

    Prior Authorization

    Prior Authorization Required

    Avlayah is subject to clinical review, including prior authorization, when requested under the member’s medical benefit. Initial requests require documentation that the individual is under 18 years of age, weighs at least 5 kg, has MPS II, and does not have advanced neurologic impairment.

    • Clinical review and prior authorization are required for applicable requests.
    • Initial-request criteria must be documented before coverage can be approved.
    Documentation Required

    Diagnostic Confirmation

    Confirm the MPS II (Hunter syndrome) diagnosis through one of the required documentation pathways: deficient iduronate 2-sulfatase enzyme activity with normal activity of another sulfatase, or a pathologic iduronate 2-sulfatase gene mutation.

    • Document deficient iduronate 2-sulfatase activity in fibroblasts or leukocytes combined with normal enzyme activity of another sulfatase; or

    Clinical Background

    Mucopolysaccharidosis II (MPS II), also known as Hunter syndrome, is an inherited lysosomal storage disease caused by deficiency of lysosomal enzymes needed to break down glycosaminoglycans. The resulting accumulation produces progressive multisystem complications. Avlayah is an enzyme replacement therapy for neurologic manifestations of MPS II in presymptomatic or symptomatic pediatric individuals weighing at least 5 kg and treated before advanced neurologic impairment.

    Definitions

    Mucopolysaccharidosis
    ConditionMucopolysaccharidosis is a group of inherited metabolic diseases.
    Underlying deficiencyDeficiency of lysosomal enzymes needed to break down mucopolysaccharides or glycosaminoglycans.
    Disease effectProgressive accumulation of glycosaminoglycans in lysosomes leads to respiratory, cardiac, skeletal and connective, neurologic, and ophthalmologic complications.
    MPS II (Hunter Syndrome)
    ConditionMucopolysaccharidosis type II, also known as Hunter syndrome.
    Enzyme deficiencyDeficiency in iduronate 2-sulfatase enzyme activity, measured in fibroblasts or leukocytes together with normal activity of another sulfatase.

    Initial Therapy

    Initial Therapy

    Initial requests may be approved when all specified age, weight, diagnostic, indication, and neurologic impairment criteria are met.

    Initial therapy

    • Age and weight: Individual is less than 18 years of age and weighs at least 5 kg.Age <18 years and weight >=5 kg
    • Diagnostic confirmation

      • Enzyme activity pathway: Deficiency in iduronate 2-sulfatase enzyme activity in fibroblasts or leukocytes combined with normal activity of another sulfatase, with documentation provided.
      • Genetic pathway:

    Continuation Therapy

    Continuation Therapy

    Continuation requests may be approved if documentation demonstrates clinically significant improvement or stabilization compared with the predicted natural history of disease.

    Clinical response or stabilization: Documentation is provided that there is clinically significant improvement or stabilization in clinical signs and symptoms of disease compared to the predicted natural history trajectory of disease.

    Examples include reduction in cerebrospinal fluid heparan sulfate or improvement in neurologic function.

    Quantity Limits

    Quantity Limits
    DrugAvlayah (tividenofusp alfa-eknm)
    Vial strength150 mg vial
    Quantity limit15 mg/kg once weekly
    Policy Summary
    PayerEmpire Bluecross
    PolicyAvlayah (tividenofusp alfa-eknm) Coverage for Neurologic Manifestations of MPS II
    Policy CodePolicy CC-0302
    Change TypeCoding update
    Effective DateOct 27, 2026
    Last ReviewSep 14, 2026
    Next Review DateN/A
    Key ActionSubmit Avlayah requests for clinical review and prior authorization with documentation supporting the applicable initial or continuation criteria.
    SourceLink
    On This Page
    Coverage CriteriaCoding InformationProvider Actions and Review RequirementsClinical BackgroundDefinitionsInitial TherapyContinuation TherapyQuantity Limits
  1. Document a pathologic iduronate 2-sulfatase gene mutation.
  2. Documentation Required

    Document Response for Continuation

    Continuation requests require documentation showing clinically significant improvement or stabilization in the disease’s clinical signs and symptoms compared with the predicted natural history trajectory.

    • Documentation may include reduction in cerebrospinal fluid heparan sulfate (HS).
    • Documentation may include improvement in neurologic function.
    • Other clinically significant improvement or stabilization may also support continuation.
    Denial Risk

    Noncovered Use or Combination Therapy

    Avlayah is not approved when the individual is using it in combination with Elaprase, when the applicable coverage criteria are not met, or for all other indications outside the policy criteria.

    • Combination therapy with Elaprase is not covered.
    • Use is not covered when the initial or continuation criteria are unmet.
    • All other indications are not covered.
    Denial Risk

    Advanced Neurologic Impairment

    Initial coverage may be denied when the individual has advanced neurologic impairment. The request must be for neurologic manifestations of MPS II and otherwise satisfy the applicable initial criteria.

    • Advanced neurologic impairment is an initial-coverage denial condition.
    Denial Risk

    Insufficient Response or Stabilization

    Continuation coverage may be denied when documentation does not demonstrate clinically significant improvement or stabilization in clinical signs and symptoms compared with the predicted natural history trajectory of disease.

    • Documented response may include reduction in cerebrospinal fluid heparan sulfate (HS) or improvement in neurologic function.
    • Insufficient documentation of improvement or stabilization creates a continuation-coverage denial risk.
    Genetic associationA pathologic iduronate 2-sulfatase gene mutation is an alternative diagnostic finding.
    Pathologic iduronate 2-sulfatase gene mutation, with documentation provided.
  3. Neurologic treatment eligibility: Request is for neurologic manifestations of MPS II and the individual does not have advanced neurologic impairment.